MedPath

Bupivacaine

Generic Name
Bupivacaine
Brand Names
Exparel, Kenalog, Marbeta, Marcaine, Marcaine With Epinephrine, Marvona Suik, P-Care M, P-Care MG, P-care, Posimir, Readysharp Anesthetics Plus Ketorolac, Readysharp-A, Readysharp-p40, Readysharp-p80, Sensorcaine, Sensorcaine With Epinephrine, Vivacaine, Xaracoll, Exparel liposomal
Drug Type
Small Molecule
Chemical Formula
C18H28N2O
CAS Number
38396-39-3
Unique Ingredient Identifier
Y8335394RO
Background

Bupivacaine is a widely used local anesthetic agent.

Indication

As an implant, bupivacaine is indicated in adults for placement into the surgical site to produce postsurgical analgesia for up to 24 hours following open inguinal hernia repair.

Bupivacaine, in liposome suspension, is indicated in patients aged 6 years and older for single-dose infiltration to produce postsurgical local analgesia. In adults, it is also indicated as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia.

Bupivacaine, in combination with meloxicam, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Bupivacaine, alone or in combination with epinephrine, is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations are recommended for each type of block indicated to produce local or regional anesthesia or analgesia. Finally, its use is not indicated in all blocks given clinically significant risks associated with use.

Associated Conditions
Acute Gouty Arthritis, Adrenocortical Insufficiency, Alopecia Areata (AA), Ankylosing Spondylitis (AS), Berylliosis, Bullous dermatitis herpetiformis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatomyositis (DM), Discoid Lupus Erythematosus (DLE), Edema of the cerebrum, Epicondylitis, Hemolytic Anemia, Hypercalcemia caused by Cancer, Keloids Scars, Leukemias, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Ocular Inflammation, Ophthalmia, Sympathetic, Osteoarthritis (OA), Pain, Labor, Polymyositis, Postoperative pain, Psoriatic Arthritis, Psoriatic plaque, Pure Red Cell Aplasia, Regional Enteritis, Rheumatoid Arthritis, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Uveitis, Acute Bursitis, Acute Idiopathic Nephrotic Syndrome, Acute Lupus Erythematosus, Acute Multiple sclerosis, Acute Rheumatic heart disease, unspecified, Acute nonspecific tenosynovitis, Cystic tumors of aponeurosis, Cystic tumors of tendon, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Inflammatory lesions of granuloma annulare, Inflammatory lesions of lichen planus, Inflammatory lesions of lichen simplex, Non-suppurative Thyroiditis, Permphigus, Severe Allergic Reactions
Associated Therapies
General Anesthesia, Local Anaesthesia therapy, Regional nerve block therapy
Clinical Trials
Related News

Comparing Dexmedetomidine With Bupivacaine Versus Bupivacaine Alone for Caudal Block in Supra - Umbilical Surgeries

Phase 2
Completed
Conditions
Anesthesia
Interventions
Drug: Dexmedetomidine
Drug: Bupivacaine
First Posted Date
2017-10-11
Last Posted Date
2018-07-17
Lead Sponsor
Cairo University
Target Recruit Count
24
Registration Number
NCT03307590
Locations
🇪🇬

Cairo University, Cairo, Egypt

Programmed Intermittent Bolus Dosing Versus Continuous Epidural Infusion for Epidural Analgesia in Abdominal Surgery.

Phase 4
Completed
Conditions
Pain, Acute
Interventions
Drug: Bupivacaine
Drug: Fentanyl
First Posted Date
2017-10-11
Last Posted Date
2020-05-12
Lead Sponsor
University of California, San Francisco
Target Recruit Count
120
Registration Number
NCT03307174
Locations
🇺🇸

University of California San Francisco, San Francisco, California, United States

Intrathecal Chloroprocaine vs. Bupivacaine for Cervical Cerclage

Phase 4
Completed
Conditions
Cervical Incompetence
Interventions
Drug: Chloroprocaine
Drug: Bupivacaine
First Posted Date
2017-10-10
Last Posted Date
2020-08-25
Lead Sponsor
Tufts Medical Center
Target Recruit Count
10
Registration Number
NCT03305575
Locations
🇺🇸

Tufts Medical Center, Boston, Massachusetts, United States

A Comparison of Exparel to Bupivacaine in TAP Block for Abdominal Gynecologic Surgery

Phase 3
Conditions
Gynecologic Cancer
Post Operative Pain
Interventions
Drug: liposomal bupivacaine
Drug: Bupivacaine
First Posted Date
2017-10-09
Last Posted Date
2017-10-09
Lead Sponsor
Abington Memorial Hospital
Target Recruit Count
128
Registration Number
NCT03304444
Locations
🇺🇸

Abington Hospital Jefferson Health, Abington, Pennsylvania, United States

0.25% Bupivacaine Versus a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka

Phase 3
Terminated
Conditions
Anesthesia
Interventions
Drug: Exparel
Drug: 0.25% bupivacaine
First Posted Date
2017-10-06
Last Posted Date
2020-03-20
Lead Sponsor
Montefiore Medical Center
Target Recruit Count
25
Registration Number
NCT03303794
Locations
🇺🇸

Montefiore Hutchinson Campus, Bronx, New York, United States

Three Protocols for Phenylephrine Administration in Cesarean Delivery

Phase 4
Completed
Conditions
Cesarean Section Complications
Spinal Anesthesia
Interventions
Drug: Single shot phenylephrine
Drug: Fixed infusion phenylephrine.
Drug: Variable infusion phenylephrine.
Drug: Bupivacaine
First Posted Date
2017-10-04
Last Posted Date
2018-12-17
Lead Sponsor
Cairo University
Target Recruit Count
217
Registration Number
NCT03302039
Locations
🇪🇬

Cairo University, Cairo, Egypt

Bunionectomy Study for Postoperative Analgesia (EPOCH 1)

Phase 3
Completed
Conditions
Postoperative Pain
Interventions
Drug: HTX-011
Drug: Saline Placebo
Drug: Bupivacaine HCl
Device: Luer-lock applicator
Device: Vial access device
First Posted Date
2017-09-28
Last Posted Date
2021-10-27
Lead Sponsor
Heron Therapeutics
Target Recruit Count
412
Registration Number
NCT03295721
Locations
🇺🇸

Springhill Medical Center, Mobile, Alabama, United States

🇺🇸

Anaheim Clinical Trials, LLC, Anaheim, California, United States

🇺🇸

Trovare Clinical Research, Inc., Bakersfield, California, United States

and more 12 locations

A Novel Analgesia Technique for ACL Reconstruction

Phase 4
Active, not recruiting
Conditions
Anterior Cruciate Ligament Injury
Interventions
Drug: Bupivacaine
Device: Ultrasound
Drug: Dexamethasone
First Posted Date
2017-09-26
Last Posted Date
2023-08-30
Lead Sponsor
Hospital for Special Surgery, New York
Target Recruit Count
78
Registration Number
NCT03292926
Locations
🇺🇸

Hospital for Special Surgery, New York, New York, United States

Neurotoxicity of Spinal Anesthesia With Ropivacaine and Bupivacaine

Phase 4
Conditions
Anaesthetic Complication Neurological
Anesthesia; Adverse Effect, Spinal and Epidural
Interventions
Drug: Bupivacaine
Drug: Ropivacaine
First Posted Date
2017-09-26
Last Posted Date
2017-12-18
Lead Sponsor
University of Rzeszow
Target Recruit Count
60
Registration Number
NCT03293472
Locations
🇵🇱

University of Rzeszow, Rzeszów, Poland

Randomized Controlled Trial for Exparel Hip Fracture

Phase 4
Completed
Conditions
Hip Fractures
Interventions
Drug: Sodium Chloride
Drug: Exparel
First Posted Date
2017-09-21
Last Posted Date
2021-03-18
Lead Sponsor
University of Massachusetts, Worcester
Target Recruit Count
55
Registration Number
NCT03289858
Locations
🇺🇸

University of Kentucky, Lexington, Kentucky, United States

🇺🇸

UMass Memorial Medical Center, Worcester, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy